BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Show moreShow less
The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.
In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases.
It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Quality Score breakdown
Overall quality36/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability31
How much profit the company makes from its sales and capital
Quality Growth62
Are margins and returns getting better?
Cashflow3
Do the profits arrive as real cash?
Financial strength33
Debt, balance sheet and risk of trouble
Investment64
Does it invest with discipline instead of growing at any price?
Low Volatility51
How calm the share price moves, does not count
Price momentum41
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 7 officers or directors sold shares worth $37.2M and none bought.
SaleMaricel ApuliChief Accounting Officer6× since Dec 8, 2025: 10,510 shares, avg. $73.02$767,398Oct 30, 202610b5-1 plan
SaleNeil KumarChief Executive Officer, Director13× since Nov 20, 2025: 725,303 shares, avg. $71.93$52.2MSep 17, 202610b5-1 plan
SaleJennifer E. CookDirector3× since Jun 15, 2026: 278,192 shares, avg. $78.80$21.9MJul 9, 202610b5-1 plan
SaleAndrea EllisDirector2× since Mar 4, 2026: 82,088 shares, avg. $68.87$5.7MJul 9, 202610b5-1 plan
SaleHannah ValantineDirector4× since Nov 12, 2025: 64,643 shares, avg. $67.56$4.4MJun 23, 2026
SaleThomas TrimarchiPresident and CFO3× since Nov 17, 2025: 44,185 shares, avg. $68.58$3.0MMay 18, 202610b5-1 plan
SaleRandal W. ScottDirector3× since Nov 17, 2025: 30,000 shares, avg. $69.75$2.1MMay 15, 202610b5-1 plan
SaleAndrew LoDirector95,599 shares at $66.11$6.3MNov 18, 2025
Plus 23 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+126.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+86.3%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.1%
’19
’21
’22
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,752.0% (2020) → −113.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Below median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−77.9% · Bottom 25%
Net margin (12 months)−59.8% · Bottom 25%
Operating margin (12 months)−3.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)192.6% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)15.38× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
BridgeBio Pharma Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of BridgeBio Pharma Inc (BBIO)?
BridgeBio Pharma Inc reported trailing-twelve-month revenue of about $946M (latest available figure, as of Sep 13, 2026).
How solid is the balance sheet of BridgeBio Pharma Inc (BBIO)?
Balance-sheet figures for BridgeBio Pharma Inc (as of Sep 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
Which stocks are comparable to BridgeBio Pharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of BridgeBio Pharma Inc (BBIO)?
The closing price on Nov 6, 2026 was $74.29. We carry closing prices from our data provider, not a live tick.
Key figures of BridgeBio Pharma Inc
How large is the market capitalisation of BridgeBio Pharma Inc (BBIO)?
The market capitalisation of BridgeBio Pharma Inc is $14.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BridgeBio Pharma Inc (BBIO)?
The price-to-sales ratio of BridgeBio Pharma Inc is 16.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BridgeBio Pharma Inc (BBIO)?
Earnings per share at BridgeBio Pharma Inc are $−3.19. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BridgeBio Pharma Inc (BBIO)?
The net margin of BridgeBio Pharma Inc is −59.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BridgeBio Pharma Inc (BBIO)?
The return on equity (ROE) of BridgeBio Pharma Inc is −1,790% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BridgeBio Pharma Inc (BBIO)?
On an EBIT basis the return on assets of BridgeBio Pharma Inc is −75.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BridgeBio Pharma Inc (BBIO)?
The operating margin of BridgeBio Pharma Inc is −3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BridgeBio Pharma Inc (BBIO)?
Revenue at BridgeBio Pharma Inc is growing +193% versus a year earlier (3y avg +86.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BridgeBio Pharma Inc (BBIO) generate?
The free cash flow of BridgeBio Pharma Inc is −$447M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BridgeBio Pharma Inc (BBIO) carry?
The net debt of BridgeBio Pharma Inc is $2.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BridgeBio Pharma Inc in the live analysis
One click puts BridgeBio Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Sep 13, 2026